Adding SGLT2 inhibitors to GLP-IRA therapy imparts CV benefit in diabetics: Circulation

USA: Initiation of SGLT2i versus sulfonylureas in diabetes patients on GLP-1RA therapy confers greater cardiovascular benefit, suggests a recent study in the journal Circulation. The results provides support for the use of SGLT2i in patients already on GLP-1RA therapy and is relevant for the prevention of cardiovascular mortality and morbidity in diabetes patients.

In large randomized trials, several sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide agonists (GLP-1RA) have shown cardiovascular benefit in patients with established cardiovascular disease or multiple risk factors. However, only few participants of the trial were on both the agents and it is not clea whether SGLT2i addition to GLP-1RA therapy has further cardiovascular benefits. To determine the same, Chintan V. Dave, Rutgers University, New Brunswick, NJ, and colleagues the reseachers identified patients adding either SGLT2i or sulfonylureas to baseline GLP-1RA. The identification was done from 3 US claims datasets (2013-2018) and the participants were 1:1 propensity score matched (PSM) adjusting for >95 baseline covariates.